Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients  

作　　者：Yaguang Zhang Xiaojing Wang Xuezhen Li Dong Xi Ruizhi Mao Xiaohui Wu Shipeng Cheng Xiaoyu Sun Chunyan Yi Zhiyang Ling Liyan Ma Qin Ning Yiru Fang Bing Sun Di Wu 

机构地区：[1]State Key Laboratory of Cell Biology,CAS Center for Excellence in Molecular Cell Science,Shanghai Institute of Biochemistry and Cell Biology,Chinese Academy of Sciences,320 Yueyang Road,200031,Shanghai,China [2]Department and Institute of Infectious Disease,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,430030,Wuhan,China [3]Clinical Research Center and Division of Mood Disorders,Shanghai Mental Health Center,Shanghai Jiao Tong University School of Medicine,200030,Shanghai,China

出　　处：《Cellular & Molecular Immunology》2020年第8期878-880,共3页中国免疫学杂志（英文版）

摘　　要：Since the outbreak of coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),more than 6 million cases are confirmed and over 300,000 cases are dead after infection.Dysfunction of immunity in COVID-19 patients has been considered as one of the fatal factors for patients,especially cytokine release syndrome and lymphopenia.1,2,3 The reduced number and increased exhaustion level of lymphocyte are associated with elevated inflammatory cytokines in COVID-19 patients.4,5 However,the mechanism of cytokine-induced lymphopenia in COVID-19 is very unclear.IL-2 is critical for the proliferation,differentiation,and function of T cells,including Tregs,CD4+,and CD8+effector cells.6 Here,we reported the negative relationship between the concentration of soluble IL-2 receptor(sIL-2R)and T-cell number in blood from COVID-19 patients.In vitro addition of recombinant CD25 could inhibit the proliferation and function of T cells from PBMC after stimulated with TCR signaling,which could be rescued by strong IL-2 signaling.Our data suggested the importance of IL-2 signaling in lymphopenia of COVID-19 patients.

关 键 词：PATIENTS lympho IMMUNITY 

分 类 号：R563.1[医药卫生—呼吸系统]